Antares Pharma, Inc. (AIS) Licenses Rights to Oxybutynin Gel to Daewoong Pharmaceuticals
Today, Antares Pharma, Inc. announced that it has licensed its Oxybutynin Gel 3% to Daewoong Pharmaceuticals Co. Ltd., exclusively, for marketing in South Korea. Antares will receive upfront payments and regulatory and sales based milestones, in addition to royalties on net sales for the product. The FDA-approved Oxybutynin Gel has demonstrated to be an effective and safe treatment for overactive bladder (OAB). The product’s active ingredient is delivered transdermally; as such, the liver metabolizes the product differently than orally administered oxybutynin, resulting in a low level of side effects, such as dry mouth and constipation. Clear and odorless, the product…